Matches 1 - 50 out of 177 1 2 3 4 >


Match Document Document Title
US20150017200 FUSION PROTEINS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF LEISHMANIASIS  
The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the Leishmania antigens K26, K39, and K9. The fusion protein is...
US20120301497 Plasmodium vivax Hybrid Circumsporozoite Protein and Vaccine  
Described in this application is a synthetic P. vivax circumsporozoite protein useful as a diagnostic reagent, for antibody production, and as a vaccine protective against infection with any...
US20110189218 Plasmodium vivax hybrid circumsporozoite protein and vaccine  
Described in this application is a synthetic P. vivax circumsporozoite protein useful as a diagnostic reagent, for antibody production, and as a vaccine protective against infection with any...
US20150093408 Lyme disease vaccine, genetic construct, recombinant protein, method for designing genetic construct, method for producing vaccine, method for producing recombinant proteins, use of recombinant proteins in the production of Lyme disease vaccine  
The present invention relates to a Lyme disease vaccine, a genetic construct, recombinant protein, method for genetic construct design, method for vaccine delivery, method for recombinant proteins...
US20120308599 VACCINE AND METHODS OF USE AGAINST STRONGYLOIDES STERCORALIS INFECTION  
The polynucleotide encoding the SSIR gene from the nematode Strongyloides stercoralis is provided, along with the polypeptide encoded by the SSIR gene. It was found that when mice were immunized...
US20110280901 Diagnosis and treatment of Trypanosoma cruzi infection and chagas disease  
Provided herein are vaccine compositions for control of Trypanosoma cruzi infection and Chagas disease. The compositions comprise plasmids encoding o GPI-anchored genes ASP-2, TcG-1, TcG2 and TcG4...
US20140170182 PRODUCTION OF A CYSTEINE RICH PROTEIN  
The present invention relates to a method for the production of correctly folded Pfs48/45. This is achieved in the lactococcus lactis when Pfs48/45 or fractions thereof are fused genetically to a...
US20130236490 Multivalent Vaccine for Filariasis  
The present invention is a multivalent vaccine for immunizing an animal against filariasis. In some embodiments, the antigens of the multivalent vaccine are protein-based, DNA-based, or a...
US20120263746 USE OF AN L3 AND/OR L5 SOURCE AS A VACCINE OR AS A DIAGNOSTIC FOR A PARASITIC DISEASE  
The invention relates to composition comprising an L3 and/or an L5 source and optionally an adjuvant for the preparation of a medicine for the treatment or prevention of a parasitic disease and to...
US20120328645 Malaria Vaccines  
Transcript profiles for irradiated and non-irradiated P. falciparum sporozoites were compared in an attempt to identify transcripts that are reproducibly perturbed by irradiation. Four loci were...
US20130177584 Recombinant Polyprotein Vaccines For the Treatment and Diagnosis of Leishmaniasis  
Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple Leishmania antigens, in...
US20110038887 Novel Vaccine Against Trypanosoma Cruzi Infection  
The present invention relates to a vaccine against Trypanosoma cruzi infection, useful in the prevention and/or treatment of the Chagas disease. More specifically, the present invention relates to...
US20140322257 FUSION PROTEINS REPRESENTING DIFFERENT NS: PROPOSAL FOR A VACCINE AGAINST ALLERGY TO MITES  
The present invention refers to recombinant DNA molecules codifying fused peptides from different allergens from Blomia tropicalis and Dermatophagoides pteronyssinus having potential usefulness in...
US20130230551 Allergy Inhibitor Compositions And Kits And Methods Of Using The Same  
Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against an a...
US20120177724 LIPID VESICLE COMPOSITIONS AND METHODS OF USE  
The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar...
US20140341918 Vaccine for Falciparum Malaria  
The invention provides compositions and methods for preventing or reducing the severity of malaria.
US20150086583 MUCIN-ASSOCIATED SURFACE PROTEIN AS VACCINE AGAINST CHAGAS DISEASE  
Use of synthetic peptides derived from Trypanosoma cruzi antigens and their use in vaccination against trypomastigote infection and Chagas disease. T. cruzi uses several surface proteins to invade...
US20120276131 ANTI-TRYPANOSOMIASIS VACCINES AND DIAGNOSTICS  
The present invention has as an object a novel genetic material coding for trans-sialidase-like proteins of African trypanosomes, and relates to the use of said genes and proteins in vaccines,...
US20100297163 RECOMBINANT MALARIA VACCINE  
The present invention refers to a recombinant malaria vaccine and a method for its manufacture.
US20140010816 TREATMENT AND PREVENTION OF MALARIA  
The present invention relates to polypeptides from Plasmodium and polynucleotides encoding the polypeptides. The invention further relates to compositions comprising the polypeptides and their use...
US20150056243 MULTICOMPONENT OR MONOCOMPONENT VACCINE TO BE USED AGAINST CHAGAS DISEASE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE FOR THE OBTENTION OF IMMUNOGEN OF SAID VACCINES, AND NUCLEIC ACID USED IN SAID PROCEDURE  
A vaccine against the Chagas disease, capable of stimulating the immune response against the trans-sialidase virulence factor of the Trypanosoma cruzi parasite, which is a multicomponent vaccine...
US20140093530 MALARIA VACCINES  
The present invention relates to a synthetic antigenic sequence which represents a combination of epitope-containing sequences from the highly polymorphic block 2 repeat region of K1-type...
US20130315945 YEAST-BASED VACCINES AS IMMUNOTHERAPY  
Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for...
US20130071420 YEAST-BASED VACCINES AS IMMUNOTHERAPY  
Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for...
US20120107342 Ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in the method  
Described is an ex vivo animal or challenge model used as a method to identify protective (e.g., recombinant) proteins and rapidly measure protective immunity in intestinal segments directed...
US20140093531 LUTZOMYIA LONGIPALPIS POLYPEPTIDES AND METHODS OF USE  
Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides...
US20140004141 Methods And Compositions Of Protein Antigens For The Diagnosis And Treatment Of Toxoplasma Gondii Infections And Toxoplasmosis  
Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen T. gondii and their use in various diagnostic tests, vaccines, and therapeutic agents. In...
US20120164167 SUB-REGION OF A PLASMODIUM PROTEIN WITH IMPROVED VACCINE POTENTIAL, AND MEDICAL USES THEREOF  
The present application relates to a sub-region of a Plasmodium protein, with improved vaccine potential, and to medical uses thereof, notably for treatment or diagnosis of malaria. The present...
US20130129766 RECOMBINANT PLASMODIUM FALCIPARUM MEROZOITE SURFACE PROTEINS 4 AND 5 AND THEIR USE  
Accordingly, the invention provides constructs in which the nucleic acids encoding Plasmodium falciparum MSP4 and MSP5, and the resulting polypeptides, have been modified. More particularly, this...
US20120082694 Recombinant Viral-Based Malaria Vaccines  
Described are vaccines against malarial infections, which are based on recombinant viral vectors, such as alpha viruses, adenoviruses, or vaccinia viruses. The recombinant viral-based vaccines can...
US20110206714 MALARIA VACCINE COMPOSITIONS AND CONSTITUENTS WHICH ELICIT CELL MEDIATED IMMUNITY  
Malaria vaccines based on polyepitope constructs that elicit cell-mediated immunity against a broad spectrum of malaria parasites and which cover the majority of HLA alleles are provided. Epitopes...
US20130129767 VACCINES AGAINST PREGNANCY-ASSOCIATED MALARIA  
The present invention relates to specific regions of the N-terminal portion of the VAR2CSA protein and to the use of such specific regions in the prevention of pregnancy-associated malaria. The...
US20140255441 VLPS CONTAINING LIGANDS AND METHODS RELATED THERETO  
This disclosure relates to immunogenic compositions and methods of enhancing an immune response to an antigen. In certain embodiments, the disclosure relates to virus-like carries comprising a...
US20120082643 Compositions and Methods for Modulating a Cytotoxic T Lymphocyte Immune Response  
The present invention provides compositions and methods for the treatment and prevention of immune disorders.
US20110212159 VACCINES  
The invention relates to use of an antigen derived from the circumsporozoite protein (CS) protein of Plasmodium falciparum which is expressed at the pre-erythrocytic stage of malarial infection in...
US20150203547 USE OF P47 FROM PLASMODIUM FALCIPARUM (PFS47) OR PLASMODIUM VIVAX (PVS47) AS A VACCINE OR DRUG SCREENING TARGETS FOR THE INHIBITION OF HUMAN MALARIA TRANSMISSION  
The inventors have identified Pfs47, a gene from the malaria parasite P. falciparum, as a key factor for survival of these parasites in the mosquito Anopheles gambiae. A. gambiae is a major...
US20150037366 METHOD FOR TREATING INFLAMMATION  
A method for reducing or alleviating inflammation in a subject includes administering to the subject a therapeutically effective amount of: (a) Ac-TMP-1 or a biologically active fragment or...
US20150125482 Recombinant polypeptide construct comprising Plasmodium falciparum circumsporozoite protein HLA class I restricted T-cell epitopes  
The invention relates to a recombinant polypeptide construct comprising epitopes from Plasmodium falciparum protein circumsporozoite protein (CSP). The epitopes contain HLA class I binding motifs...
US20120321653 NOVEL CHIMERIC POLYNUCLEOTIDES AND POLYPEPTIDES ENABLING THE SECRETION OF A POLYPEPTIDE OF INTEREST IN COMBINATION WITH EXOSOMES AND USES THEREOF  
The present invention provides a chimeric polypeptide comprising a plurality of polypeptide domains that are capable of being secreted in combination with membrane vesicles and in particular...
US20130259890 PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE VACCINE GENE OPTIMIZATION FOR SOLUBLE PROTEIN EXPRESSION  
The present invention provides novel nucleotide sequence and other constructs used for expression of novel recombinant P. falciparum circumsporozoite proteins in bacterial cells such as E. coli....
US20140212452 Vaccination of Animals to Elicit A Protective Immune Response Against Tick Infestations and Tick-Borne Pathogen Transmission  
Two antigenic and immunogenic proteins of the cattle tick, Rhipicephalus microplus, and the genes encoding these proteins, are effective for eliciting a protective immune response that controls...
US20130315947 Vaccination of Animals to Elicit a Protective Immune Response Against Tick Infestations and Tick-Borne Pathogen Transmission  
Two antigenic and immunogenic proteins of the cattle tick, Rhipicephalus microplus, and the genes encoding these proteins, are effective for eliciting a protective immune response that controls...
US20120231029 ENHANCED MALARIA MSP-1 SUBUNIT VACCINE  
Recombinant subunit proteins derived from the MSP-1 C-terminal region of the parasite Plasmodium falciparum are described that have enhanced immunogenic properties. Selected regions of p33 have...
US20130273094 VACCINES AGAINST TOXOPLASMA GONDII  
Vaccines are disclosed against parasites. The vaccines include peptides in an immunological composition. In particular, the parasite is Toxoplas gondii.
US20150071876 COMBINED MEASLES-MALARIA VACCINE  
A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens is...
US20120308598 MALARIA VACCINES BASED ON APICOMPLEXAN FERLINS, FERLIN-LIKE PROTEINS AND OTHER C2-DOMAIN CONTAINING PROTEINS  
The present invention relates to peptides comprising at least one antigenic determinant or epitope of an apicomplexan Ferlin, Ferlin-like protein and/or another C2-domain containing protein for...
US20110311571 METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING MALARIA USING AN INVASION LIGAND DIRECTED TO A PROTEASE-RESISTANT RECEPTOR  
This invention relates to an immunogenic molecule comprising a contiguous amino acid sequence of an invasion ligand of a strain of Plasmodium falciparum, the invasion ligand capable of binding to...
US20110117120 Plasmodium falciparum HLA class I restricted T-cell epitopes  
The invention relates immunogenic polypeptides and epitopes from Plasmodium falciparum protein AMA1. The epitopes contain HLA class I binding motifs and stimulate an anti-malaria CD8+ T-cell...
US20110008381 SUPPRESSION OF ALLERGIC INFLAMMATION BY ASCARIS HEME-BINDING PROTEIN (HBP)  
This invention relates, e.g., to a method for suppressing inflammation (e.g. allergic inflammation, for example asthma caused by ragweed), a Th1-mediated condition and/or a Th2-mediated condition...
US20140348870 IMMUNOGENIC PLASMODIUM FALCIPARUM ANTIGEN COMPOSITIONS AND USES THEREOF  
Contemplated compositions and methods employ selected antigens form Plasmodium falciparum and can be used as a vaccine, therapeutic agent, and/or diagnostic tool. Especially preferred antigens are...

Matches 1 - 50 out of 177 1 2 3 4 >